medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2004, Number 4

<< Back Next >>

Rev Biomed 2004; 15 (4)

Seroprevalence of antibodies against Toxoplasma gondii in Cuban patients with HIV infection

Martín-Hernández I, García-Izquierdo SM

Language: Spanish
References: 34
Page: 215-220
PDF size: 35.46 Kb.


ABSTRACT

Introduction. With the infection of the human immunodeficiency virus (HIV), Toxoplasma gondii has emerged as an important opportunistic pathogenic agent. This parasitical infection involves a variety of host organs, particularly the gastrointestinal tract, lungs, myocardium, brain, and eyes. Between 10-50% of HIV-infected patients who are seropositive for T. gondii develop Toxoplasma encephalitis. The incidence of this parasite in HIV-infected principally patients depends on the existence of latent toxoplasmosis in the affected population.
Material and methods. UMELISA Toxoplasma®, was used to study the presence of IgG anti-Toxoplasma antibodies in 107 patients with HIV and 123 blood donors as a control group. The presence of IgM antibodies was determined using the commercial kit Toxonostika IgM II.
Results: The prevalence was 71,96 % (77/107) in patients and 71,54 % (88/123) in blood donors, with no significant difference between the two groups. No cases were seropositive to IgM anti-Toxoplasma antibodies. No relationship between seroreactivity and CD4 T-cell counts in HIV/AIDS patients was found.
Discussion. The high prevalence of T. gondii antibodies in both groups suggests that this zoonosis is endemic in Cuba. The high morbidity and mortality of toxoplasmosis in the HIV-infected population, justifies the routine determination and monitoring of anti-Toxoplama antibodies in these patients.


REFERENCES

  1. Wong SY, Remington JS. Biology of Toxoplasma gondii. AIDS 1993; 7: 299-318.

  2. Okome M, Mbounja ME, Kombila M. Spectrum of opportunistic infections in subjects infected with HIV. Sante 2000; 10: 329-37.

  3. Maiga I, Kiemtore P, Tounkara A. Prevalence of anti- Toxoplasma in patients with acquired immunodeficiency syndrome and blood donors in Bamako. Bull Soc Pathol Exot 2001; 94: 268-70.

  4. Góngora RA, Gónzalez P, Castro C, Alvarez R, Pavia N, Lara D, et al. Anticuerpos contra Toxoplasma gondii en pacientes con VIH en Yucatán. Rev Invest Clin 1998; 50: 419-22.

  5. Luft BJ, Hafner R, Korzun AH. Toxoplasmic encephalitis in patients with adquired immunodeficiency syndrome. N Engl J Med 1993; 329: 995-1000.

  6. Kasper LH. Toxoplasma infection. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrinson’s Principles of Internal Medicine. 15 th ed. New York: McGraw-Hill 2001. p. 1222-7.

  7. Grant HI, Gold JW. Toxoplasma gondii serology in HIVinfected patients, the development of central nervous system toxoplasmosis in AIDS. AIDS 1990; 6: 519-21.

  8. Holliman RE. Serological study of the prevalence of toxoplamosis in asympotamatic patients infected with human immunodeficiency virus. Epidemiol Infect 1990; 105:415-8.

  9. Hayde M, Salzer HR, Gittler G, Aspock H, Pollak A. Microparticle enzyme immunoassay (MEIA) for Toxoplasma specific immunoglobulin G in comparison to the Sabin-Feldman dye test. A pilot study. Wien Klin Wochenschr 1995; 107:133-6

  10. Pinon JM, Foudrinier F, Mougeot G, Marx C, Aubert D, Toupance O, et al. Evaluation of risk and diagnostic value of quantitative assays for anti-Toxoplasma gondii immunoglobulin A (IgA), IgE and IgM and analytical study of specific IgG in immunodefient patients. J Clin Microbiol 1995; 33: 878-84.

  11. Rodríguez MS, Fernández T, Ginorio D, Capó V, Garcia G, Cox R. Contribución al conocimiento de la encefalitis por Toxoplasma en pacientes VIH/SIDA 1998-2001. II Foro en VIH / SIDA / ITS de América Latina y el Caribe. Cuba, Abril 2003. CD-ROOM Memorias Foro 2003.

  12. Medina E. Características clínicas de la infección por el VIH-SIDA en la provincia Holguín, Cuba. Años 1986 al 2000. II Foro en VIH / SIDA / ITS de América Latina y el Caribe. Cuba, Abril 2003. CD-ROOM Memorias Foro 2003.

  13. Véliz DM. Mortalidad de la epidemia del VIH/SIDA en Pinar del Río 1991-2002. II Foro en VIH / SIDA / ITS de América Latina y el Caribe. Cuba, Abril 2003. CD-ROOM Memorias Foro 2003.

  14. Fernández JL. Screening Technology Development. The Cuban experience. 8th International Symposium on Neonatal Screening and Inaural Meeting of International Society for Neonatal Screening. Sidney, Australia: Abstract Book; 1991.

  15. Sigarroa A. Manual de clases prácticas de biometría y diseño experimental. 1a ed. Cuba: Editora Pueblo y Educación; 1987.

  16. Góngora-Biachi RA, Gónzalez-Martínez P, Puerto F, Castro-Sansores C. Inmunopatogénesis de la infección por el virus de Inmunodeficiencia humana. Rev Biomed 1991; 2: 207-16.

  17. Acosta C, Pérez X, García R. Presencia de anticuerpos IgG anti-Toxoplasma gondii en embarazadas residentes en Ciudad de la Habana. Rev Biomed 2001; 12: 250-54.

  18. González T, Bacallao J, García C, Molina JR. Prevalencia de anticuerpos anti-Toxoplasma gondii en una población de mujeres embarazadas en Cuba. Gac Méd Méx 1991; 131: 499-03.

  19. Collazo JE, López R, Ginorio D, Llamos R, Contreras R. Anticuerpos IgG anti-Toxoplasma gondii en pacientes con síntomas atribuíbles a toxoplasmosis. Biomed 1993; 13: 179-82.

  20. Martinez R, Bacallao R, Alberti E, Alfonso I. Prevalence of toxoplasmosis in pregnant women of the province of La Habana. Rev Inst Trop Sao Paulo 1994; 36: 445-50.

  21. Thulliez Ph, Derouin F, Peyron F, Wallon M, Candolfi E. Toxoplasmosis and diagnostic. 1a ed. Madrid: Coimpress SA; 1996. p. 11.

  22. Sánchez A, Martín I, García S. Estudio de reactividad a Toxoplasma gondii en embarazadas de las provincias Ciudad de la Habana y Pinar del Río, Cuba. Bioquimia 2003; 111: 3-8.

  23. López R, Fano R, Contreras R, Font L. Anticuerpos IgG anti- Toxoplasma gondii en cubanos donantes de sangre. Rev Lat Am Microbiol 1993; 35: 207-10.

  24. Martín I, García SM. Prevalencia de anticuerpos IgG contra Toxoplasma gondii en donantes de sangre cubanos. Rev Biomed 2003; 14: 247-51.

  25. Pauwels A, Meyohas MC, Eliaszewicz M, Legendre C, Mougeot G, Frottier J, et al. Toxoplasma colitis in the acquired imunodeficiency syndrome. Am J Gastroenterol 1992; 87: 518-9.

  26. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1993; 327: 1643-8.

  27. Reparaz PJ, Regalados DCJ, Urix Y, Ayestran J. Lesiones cerebrales pacientes con sindrome de inmunodeficiencia adqurida. Enferm Infec Microbiol 1991; 9: 85-9.

  28. Nissapatorn V, Kamarulzaman A, Init I, Tan LH, Rohela M, Norliza A, et al. Seroepidemiology of toxoplasmosis among HIV-infected patients and healthy blood donors. Med J Malaysia 2002; 57: 304-10.

  29. Sukthana Y, Chintana T, Lekkla A. Toxoplasma gondii antibody in HIV-infected persons. J Med Assoc Thai 2000; 83: 681-4.

  30. Galvan ML, Valdez V, Vargas G, Jimenez O, Garcia C, Vielma M. Prevalence of IgG and IgM anti-Toxoplasma antibodies in patients with HIV and acquired immunodeficiency syndrome (AIDS). Rev Soc Bras Med Trop 1997; 30: 465-7.

  31. Zufferey J, Sugar A, Rudaz P, Bille J, Glauser MP, Chave JP. Prevalence of latent toxoplasmosis and serological diagnosis of active in HIV-positive patients. Eur J Clin Microbiol 1993;12:591-5.

  32. Wainstein MU, Ferreira L, Wolfenbuttel L, Golbspan L, Sprint E, Kronfeld M, et al. Achados neuropatológicos na síndrome da imunodeficiência adquirida (SIDA). Revisão de 138 casos. Rev Soc Bras Med Trop 1992; 25: 95-9.

  33. Stepick-Biek P, Thulliez P, Araujo FG, Remington JS. IgA antibodies for the diagnosis of congenital and acquired toxoplasmosis. J Med Microbiol 1990; 32: 25-31.

  34. Holliman RE. Toxoplasmosis and the acquired immune deficiency syndrome. J Infect Dis 1988; 16: 121-8.




2020     |     www.medigraphic.com